Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).

British journal of cancer - 1 Aug 2026

Barraud S, Roussel-Simonin C, Pautier P, Italiano A, Massard C, Hollebecque A, Michels J, Blanc-Durand F, Ouali K, Rouleau E, Leary A

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitors (ICI) are approved for metastatic cervical cancer (mCC) after platinum failure, but only a minority of patients derive durable benefit. We aimed to compare long-term responders (LTR) and non-long-term responders (NLTR) to ICI and to identify clinical and molecular predictors of long-term response. METHODS: We retrospectively reviewed patients with mCC treated with ICI at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Immune Checkpoint Inhibitors

Share to Mutation

Share to Neoplasm Metastasis

Share to Progression-Free Survival

Share to Uterine Cervical Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42151561
DOI: 10.1038/s41416-026-03438-6
PMCID: PMC13427743

Genes

PIK3CA
STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).PMID 42151561Read ↗

Transcriptomic Profiling Reveals Predictive Markers of Response to Concurrent Chemoradiotherapy plus Immune Checkpoint Inhibition in Cervical CancerSemantic proximity Read ↗

Real-world multicenter study of immune checkpoint inhibitors in advanced cervical cancer across HPV-associated and HPV-independent subtypesSemantic proximity Read ↗

Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancerSemantic proximity Read ↗

Real-World Outcomes of Second-Line Pembrolizumab in Urothelial Carcinoma: A Multicenter Analysis from the Campania Oncological Network (ROC)Semantic proximity Read ↗

Exploratory evaluation of the somatic and immunologic landscape of primary and metastatic cervical cancer to better inform future clinical trial development.Semantic proximity Read ↗

Immune Checkpoint Inhibitor Resistance in Genitourinary Cancers: Mechanisms, Biomarkers, and Emerging Therapeutic StrategiesSemantic proximity Read ↗

Chemoradiotherapy-induced ACKR2+ tumor cells drive CD8+ T cell senescence and cervical cancer recurrenceSemantic proximity Read ↗

Decreased local immune response and retained HPV gene expression during chemoradiotherapy are associated with treatment resistance and death from cervical cancerSemantic proximity Read ↗

Molecular landscape of recurrent cervical cancerSemantic proximity Read ↗

Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcomeSemantic proximity Read ↗

Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer.Semantic proximity Read ↗

Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.